What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Epakitin for Cats and Dogs: Phosphate Binder Guide

Name: Epakitin for Cats and Dogs: Phosphate Binder Guide
Creator: Dr. Zubair Khalid

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Epakitin is an oral nutritional supplement used in cats and dogs with chronic kidney disease (CKD) to help lower the amount of phosphate the body absorbs from food. Its two active ingredients are chitosan, a fiber derived from shellfish shells, and calcium carbonate, a mineral that also acts as an antacid. Together they bind phosphate inside the digestive tract so that less of it reaches the bloodstream. Epakitin is given with meals because binding only works when food phosphate and the supplement are present in the gut at the same time. It is a supportive therapy, not a cure for kidney disease, and it does not replace a phosphate-restricted renal diet.

This guide explains what Epakitin is, why phosphate control matters so much in CKD, how the product is given, what monitoring your veterinarian will schedule, and how it fits alongside the other parts of a kidney care plan. Dosing is set by body weight according to the product label and your veterinarian's direction, so no specific milligram or scoop amount is given here.

At a Glance

Feature	Detail
Active ingredients	Chitosan and calcium carbonate
Product type	Oral nutritional supplement, phosphate binder
Species	Cats and dogs
Primary use	Supportive phosphate control in chronic kidney disease
How it is given	By mouth, mixed with or given around meals
Timing requirement	Must be given with food so it can bind dietary phosphate
Onset of effect	Works within the digestive tract at each meal, not as a one-time dose
Duration of action	Acts on the phosphate present in the meal it accompanies
Prescription status	Sold as a supplement, often through a veterinarian
Dose	By body weight per the product label and veterinarian direction
Monitoring	Serum phosphate, calcium, and renal values over time

What Epakitin Is and What It Contains

Epakitin is a dietary supplement formulated for dogs and cats with reduced kidney function. The two named ingredients, chitosan and calcium carbonate, are the same class of agents studied in veterinary CKD research. A masked randomized controlled trial in dogs with naturally occurring CKD tested a commercial supplement containing chitosan, phosphate binders, and alkalinizing agents alongside a renal diet. At 44 weeks, dogs receiving the supplement had roughly a 50 percent lower mortality rate from uremic crises compared with dogs receiving a placebo plus the same diet [1]. That trial supports the concept of combining chitosan-based phosphate binding with a renal diet, which is the role Epakitin is designed to fill.

A separate long-term study followed cats in IRIS stages 3 and 4 CKD for 360 days. Ten cats received a dietary supplement containing calcium carbonate, calcium-lactate gluconate, chitosan, and sodium bicarbonate, while ten control cats received only a renal diet. The supplemented cats showed reduced serum phosphorus and increased serum bicarbonate values [2]. This is direct feline evidence that a chitosan and calcium carbonate combination can move phosphorus in the right direction in advanced kidney disease.

Epakitin itself is not a drug in the regulatory sense. It is marketed as a supplement, which means it does not carry the same approval pathway as a prescription pharmaceutical. In the United States, supplements are not reviewed by the FDA for efficacy before sale the way drugs are, so quality and consistency rest with the manufacturer. Ask your veterinarian whether the specific product you were given is one they trust and stock.

Why Phosphate Control Matters in Kidney Disease

Phosphate is a mineral your pet needs, but the kidneys are responsible for clearing the excess. When kidney function declines, phosphate accumulates. This is not a minor laboratory abnormality. In dogs with CKD, hyperphosphatemia is associated with shorter survival. A prospective study of 27 azotemic dogs found that hyperphosphatemia carried a hazard ratio of 3.20 for death, meaning dogs with high phosphorus were substantially more likely to die during the study period than dogs with normal phosphorus [3]. A separate longitudinal study of dogs with CKD identified hyperphosphatemia, anemia, and low body condition score as factors related to decreased survival [4].

The problem starts earlier than most owners realize. Phosphate retention begins before serum phosphorus ever rises above the reference range. A study of urinary fractional excretion of phosphorus in dogs found that the fraction of filtered phosphate appearing in urine increases progressively as CKD advances, as a compensatory attempt to keep phosphorus normal. In late stages, some dogs with stage 4 CKD actually showed normal or reduced fractional excretion despite hyperphosphatemia, meaning the kidney had lost its ability to dump the excess [5].

The body also fights phosphate retention with hormones. Fibroblast growth factor 23 (FGF-23) is a phosphatonin, a hormone that tells the kidney to excrete phosphate and blocks activation of vitamin D. FGF-23 rises first in the sequence of changes that make up CKD-mineral and bone disorder, before phosphorus and parathyroid hormone (PTH) become abnormal [6]. In dogs, plasma FGF-23 concentrations increase with CKD severity and are significantly higher in IRIS stages 3 and 4 than in stages 1 and 2 [7]. One study found that 73.1 percent of dogs in IRIS stage 2 had elevated FGF-23, compared with only 30.8 percent that had hyperparathyroidism, showing that this hormonal response is an early event [8].

When phosphate retention outpaces these defenses, PTH rises. This is renal secondary hyperparathyroidism. A study of 54 dogs with naturally occurring CKD found hyperparathyroidism in 75.9 percent of them, climbing from 36.4 percent in stage 1 to 100 percent in stage 4. Hyperphosphatemia was present in 68.5 percent overall, rising from 18 percent in stage 1 to 100 percent in stage 4 [9]. The same pattern appears in cats. Controlling phosphate is one of the few interventions that reliably interrupts this cascade, which is why phosphate binders are a mainstay of CKD management [10].

How Epakitin Binds Phosphate

Phosphate binders work by chemistry, not by altering kidney function. When your pet eats, phosphate from the food enters the stomach and small intestine. A binder given at that same time binds to some of that phosphate, forming a compound the gut cannot absorb. The bound phosphate then leaves the body in the stool instead of entering the bloodstream. This is why timing matters so much. A binder given on an empty stomach has nothing to bind and simply passes through.

Calcium carbonate binds phosphate by forming insoluble calcium phosphate in the gut. It also neutralizes stomach acid, which is why it appears in antacids for people. In the veterinary literature, calcium carbonate is a recognized intestinal phosphate binder used alongside dietary phosphorus restriction to correct phosphorus retention and maintain normal blood calcium [10]. Comparative pharmacology work in rats with chronic renal failure showed that calcium carbonate reduced urinary phosphate excretion, a marker of how much phosphate the body absorbed, though less potently than lanthanum carbonate or aluminum hydroxide [11].

Chitosan works differently. It is a polysaccharide derived from chitin, the material in shellfish shells. Chitosan is not absorbed from the gut. It binds phosphate and other charged molecules in the intestinal contents and carries them out in feces. The dog trial that reduced uremic crisis mortality used a supplement built around chitosan plus phosphate binders and alkalinizing agents [1], and the feline long-term study used chitosan alongside calcium carbonate and related calcium salts [2]. Chitosan also has a mild alkalinizing effect, which can be useful because metabolic acidosis is common in advanced CKD.

The practical takeaway is that Epakitin does its job only in the presence of food. Every meal that contains phosphate needs to be paired with the supplement. If your pet is a grazer who nibbles all day, or if you skip a meal because of poor appetite, the binding opportunity for that food is lost.

The flowchart below shows the decision path for starting and continuing a phosphate binder in CKD.

flowchart TD
    A[Pet diagnosed with CKD] --> B[Check serum phosphate]
    B --> C{Phosphate above target}
    C -->|No| D[Recheck in 4 to 8 weeks]
    C -->|Yes| E[Start renal diet]
    E --> F[Recheck phosphate]
    F --> G{Still above target}
    G -->|No| H[Continue diet and monitor]
    G -->|Yes| I[Add phosphate binder with meals]
    I --> J[Recheck phosphate calcium and renal values]
    J --> K{Phosphate controlled}
    K -->|Yes| L[Continue and monitor]
    K -->|No| M[Adjust diet binder or both with vet]

How Epakitin Is Given

Epakitin is given by mouth, mixed into food or administered around mealtime. The label and your veterinarian determine the amount, based on your pet's body weight. Do not guess at a dose or scale it up from another pet. If your veterinarian changes the amount, follow the new instruction exactly.

The single most important rule is to give it with food. Binding requires food phosphate to be present in the gut at the same time as the supplement. Give it at the start of the meal, mixed thoroughly into the food, or as directed on the label. If your pet eats half the bowl and walks away, the supplement that went into the uneaten portion does nothing.

A few practical points help owners succeed:

Mix the supplement evenly through a small amount of food your pet will finish, then offer the rest of the meal.
If your pet is on a prescription renal diet, keep feeding that diet. The binder supplements the diet, it does not replace it.
If your pet takes other medications, ask your veterinarian about spacing. Calcium carbonate can interfere with absorption of some drugs, so timing may need to be adjusted.
If a meal is skipped because of nausea or poor appetite, do not give the binder on its own. Address the appetite problem with your veterinarian first.
Keep a simple log of meals and doses so you and your veterinarian can see whether binding is happening consistently.

The once-daily dosing convenience seen in some newer renal supplements is worth noting because it improves compliance in hyporexic pets or those on many medications [12]. If your pet's regimen allows fewer daily doses, that can make a real difference in whether the supplement actually gets given. Ask your veterinarian whether your pet's specific product and schedule can be simplified.

What Epakitin Does Not Do

Epakitin does not cure chronic kidney disease. There is no supplement or medication that reverses the structural damage of CKD. The goal of phosphate binding is to slow the metabolic consequences of phosphate retention and reduce the burden on the body, not to restore kidney tissue.

Epakitin does not replace a phosphate-restricted renal diet. Dietary phosphorus restriction is the foundation of phosphate control, and binders are added when diet alone is not enough [10]. A renal diet lowers the phosphate load entering the gut. A binder captures part of what remains. Skipping the diet and relying on the binder alone leaves far more phosphate to manage than the binder can handle.

Epakitin does not correct every mineral abnormality in CKD. It targets phosphate and, through calcium carbonate, provides some calcium and alkalinizing effect. It does not directly suppress PTH, restore calcitriol, or normalize FGF-23. Those are separate therapeutic targets your veterinarian may address with other interventions [10][13].

Epakitin does not treat acute kidney injury. The evidence base for chitosan and calcium carbonate binders is in chronic kidney disease. PTH is elevated in acute kidney injury too, and increases with AKI grade, but that is a different clinical situation requiring different management [14].

Side Effects and What to Do About Them

The most common issues with any oral phosphate binder are gastrointestinal. Vomiting, diarrhea, reduced appetite, and stool changes are the effects owners notice. In the feline long-term study, owners completed questionnaires about appetite, palatability, vomiting, and diarrhea, and the supplement was tolerated well enough to be given for 360 days [2]. Tolerance varies by individual pet and by how the product is mixed into food.

Calcium carbonate adds a specific consideration: calcium. Because it contains calcium, it can raise serum calcium if given in excess or if your pet's calcium regulation is already abnormal. Hypercalcemia is a real risk in CKD patients, and it is one reason monitoring serum calcium matters as much as monitoring phosphate. The veterinary literature is explicit that the goal of binder therapy is to correct phosphorus retention while maintaining normocalcemia [10].

If your pet vomits after a dose, do not simply repeat it. Repeated vomiting can mean the binder is irritating the stomach, the dose is too high, or something else is going on. Contact your veterinarian. If diarrhea develops, the same applies. Never increase the dose on your own to try to bring phosphorus down faster. More binder does not mean better control, and it can push calcium in the wrong direction.

Chitosan is derived from shellfish. If your pet has a known shellfish allergy, tell your veterinarian before starting. Shellfish allergy in pets is uncommon, but the ingredient source is worth flagging.

Which Pets Should Not Receive Epakitin

Epakitin is intended for cats and dogs with CKD and elevated or trending-high phosphate. It is not appropriate for every pet.

Pets that should not receive it without specific veterinary direction include:

Pets with normal or low serum phosphate. Binding phosphate when it is not elevated can drive phosphorus too low and disrupt other mineral balances.
Pets with hypercalcemia or a history of calcium disorders. The calcium carbonate component can worsen high calcium.
Pets with known shellfish allergy, because of the chitosan source.
Pets with significant gastrointestinal disease, active vomiting, or diarrhea, until those issues are resolved.
Pets in acute kidney injury or other acute illnesses, unless a veterinarian specifically recommends it.
Very small pets, unless a veterinarian has calculated an appropriate amount. The label and your veterinarian set the dose by body weight.

Pregnancy and nursing status should be discussed with your veterinarian. There is no established evidence base for binder use in breeding animals, so the decision is individual.

Monitoring: Phosphate, Calcium, and Renal Values

Monitoring is what separates safe binder use from guesswork. Three lab values matter most.

Serum phosphate is the primary target. Your veterinarian will set a target range based on your pet's IRIS stage and clinical picture, then check phosphorus periodically to see whether the binder plus diet is holding it there. If phosphorus stays high, the plan needs adjustment. If it drops too low, the binder may need to be reduced.

Serum calcium is the safety check. Because Epakitin contains calcium carbonate, calcium can drift upward. The therapeutic goal is phosphate control with normal calcium [10]. In dogs with chronic renal failure and metabolic acidosis, ionized calcium, the biologically active fraction, can differ widely from total calcium, and 56 percent of dogs in one study were hypocalcemic by ionized calcium even though only 8 percent looked hypocalcemic by total calcium [15]. This is why your veterinarian may measure ionized calcium rather than relying on total calcium alone.

Renal values, including creatinine and symmetric dimethylarginine (SDMA), track the underlying disease. SDMA was the only glomerular filtration rate marker that showed differences across time in early CKD stages in one longitudinal study, making it useful for tracking progression [4]. Creatinine and blood urea nitrogen remain part of the standard panel. Your veterinarian will also watch for progression between IRIS stages.

PTH and FGF-23 are not routine monitoring tests in most practices, but they are relevant to why phosphate control matters. FGF-23 rises early and predicts development of hyperphosphatemia in normophosphatemic dogs with CKD, with a concentration above 528 pg/mL associated with a shorter time to hyperphosphatemia and to CKD progression [6]. PTH rises as phosphate retention worsens, and in dogs with CKD it correlates with both creatinine and phosphate concentrations [14].

Decision Table: When to Start, Monitor, and Reassess

Stage of care	What to do	What to check	When to reassess
Early CKD, phosphate normal	Feed an appropriate renal diet, monitor	Serum phosphate, creatinine, SDMA	Every 4 to 8 weeks initially, then per veterinarian
Phosphate rising or above target on diet alone	Discuss adding a phosphate binder with meals	Serum phosphate, calcium, renal panel	2 to 4 weeks after starting, then per veterinarian
Binder started	Give with every phosphate-containing meal	Serum phosphate, calcium, renal panel, appetite, stool	2 to 4 weeks, then every 4 to 8 weeks if stable
Phosphate controlled	Continue diet plus binder	Serum phosphate, calcium, renal panel	Every 4 to 8 weeks, or as directed
Phosphate still high	Review diet compliance, meal timing, dose with veterinarian	Serum phosphate, calcium, diet history	2 to 4 weeks after any change
Phosphate too low or calcium high	Reduce or stop binder per veterinarian	Serum phosphate, calcium, ionized calcium	Promptly, as directed
Vomiting, diarrhea, or appetite loss	Contact veterinarian before continuing	Clinical exam, hydration, labs	Same day or next available appointment
Progression to a higher IRIS stage	Reassess the whole plan	Full renal and mineral panel	At the visit where progression is identified

This table is a framework, not a prescription. Your veterinarian sets the actual intervals based on your pet's stage, other conditions, and response to treatment.

How Epakitin Compares With Other Phosphate Binders

Several phosphate binders are used in veterinary medicine, and they differ in potency, calcium content, and risk profile.

Calcium carbonate is the calcium-based binder in Epakitin. It is effective and inexpensive, and it provides some alkalinizing benefit. Its main limitation is the calcium load, which matters in pets prone to hypercalcemia.

Aluminum hydroxide is a non-calcium binder. It avoids the calcium issue but carries its own risk. A study of serum aluminum in 176 cats found that 9 of 21 cats with CKD receiving aluminum hydroxide had serum aluminum concentrations above 100 ng/mL, the threshold above which serious complications such as encephalopathy, anemia, and bone disease are reported in dogs and people. Cats receiving aluminum hydroxide had significantly higher mean serum aluminum than cats not receiving it [16]. This is why aluminum-based binders are usually reserved for specific situations and monitored carefully.

Lanthanum carbonate is another non-calcium binder. Comparative pharmacology work in rats with chronic renal failure found lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion more than calcium carbonate, which in turn was more effective than sevelamer hydrochloride [11]. Lanthanum is used in veterinary patients when calcium-based binders are not suitable, but it is typically more expensive.

Sevelamer is a non-calcium polymer binder. In the same comparative study it was the least potent of the binders tested [11]. It is sometimes chosen when calcium load is a concern.

The choice among these agents depends on your pet's calcium status, other lab values, cost, and how well your pet tolerates the product. Epakitin's combination of chitosan and calcium carbonate makes it a reasonable option for many pets, particularly when some alkalinizing support is welcome, but it is not the right choice for every patient.

Questions to Ask Your Veterinarian

Bring these questions to your next appointment:

What is my pet's current IRIS stage, and what phosphate target are we aiming for?
Is diet alone enough right now, or is it time to add a binder?
How much Epakitin should my pet receive, based on body weight and the label?
Exactly how should I give it with meals, and what if my pet does not finish the bowl?
How often will we recheck phosphate, calcium, and renal values?
Should we measure ionized calcium instead of total calcium?
Does Epakitin interact with any of my pet's other medications?
What signs should make me call you right away?

Limitations and When to Contact a Veterinarian

This article is educational and is not a substitute for veterinary diagnosis or treatment. Every pet with CKD is an individual, and the right plan depends on stage, concurrent diseases, lab trends, appetite, and how well your pet tolerates each intervention. Your veterinarian is the only person who can set a dose, interpret your pet's labs, and adjust the plan.

Contact your veterinarian promptly if any of the following occur:

Your pet vomits repeatedly or cannot keep food or the supplement down.
Diarrhea develops or worsens.
Your pet stops eating or shows a clear drop in appetite.
Your pet becomes lethargic, weak, or unusually quiet.
You notice muscle twitching, tremors, or abnormal behavior.
Your pet drinks or urinates far more or far less than usual.
You see blood in the stool or vomit.
Your pet's breathing changes or they seem to be in discomfort.
You miss several doses or cannot get your pet to take the supplement with meals.
Your pet's lab values change and you are unsure what the new numbers mean.

Do not adjust the dose, stop the supplement, or change the diet on your own. Phosphate control is a balance, and moving one part of the plan without guidance can push another part out of range.

Frequently Asked Questions

What is Epakitin used for?

Epakitin is a phosphate binder used in cats and dogs with chronic kidney disease to reduce how much phosphate the body absorbs from food. It supports phosphate control alongside a phosphate-restricted renal diet.

Does Epakitin cure kidney disease?

No. Epakitin does not cure or reverse chronic kidney disease. It helps manage phosphate retention, which is one consequence of reduced kidney function.

How is Epakitin given?

Epakitin is given by mouth with meals, mixed into food or administered around mealtime. It must be given with food because binding requires food phosphate to be present in the gut at the same time.

What is the dose of Epakitin?

The dose is based on your pet's body weight according to the product label and your veterinarian's direction. Do not guess at an amount or scale it from another pet.

Can I give Epakitin without food?

No. Giving it without food defeats the purpose, because there is no dietary phosphate for it to bind. If a meal is skipped, skip the binder and talk to your veterinarian about the appetite problem.

Does Epakitin replace a renal diet?

No. Dietary phosphorus restriction is the foundation of phosphate control. Epakitin supplements the diet and does not replace it.

What should be monitored while my pet takes Epakitin?

Your veterinarian will monitor serum phosphate, serum calcium, and renal values such as creatinine and SDMA. Ionized calcium may also be checked because calcium can drift upward with calcium-based binders.

What are the side effects of Epakitin?

The most common side effects are gastrointestinal, including vomiting, diarrhea, and reduced appetite. Because it contains calcium carbonate, it can also raise serum calcium, which is why monitoring matters.